Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)
CNY 3.85
(-4.7%)
CNY 3.85
(-4.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -298.6 Million CNY | -134.53% |
| 2022 | 370.04 Million CNY | 23.18% |
| 2021 | 353.4 Million CNY | -25.3% |
| 2020 | 412.69 Million CNY | -11.44% |
| 2019 | 548.39 Million CNY | -31.6% |
| 2018 | 757.86 Million CNY | 15.35% |
| 2017 | 706.83 Million CNY | 5.34% |
| 2016 | 663.62 Million CNY | 9.04% |
| 2015 | 563.64 Million CNY | 28.15% |
| 2014 | 462.04 Million CNY | 15.52% |
| 2013 | 404.92 Million CNY | 10.25% |
| 2012 | 324.4 Million CNY | 14.45% |
| 2011 | 288.35 Million CNY | 47.45% |
| 2010 | 210.45 Million CNY | 46.56% |
| 2009 | 158.28 Million CNY | 25.63% |
| 2008 | 125.22 Million CNY | 15.22% |
| 2007 | 108.92 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 53.07 Million CNY | -65.39% |
| 2024 Q2 | 103.62 Million CNY | 26.47% |
| 2024 Q1 | 150.74 Million CNY | 120.05% |
| 2023 Q4 | -524.68 Million CNY | -3049.52% |
| 2023 FY | - CNY | -134.53% |
| 2023 Q1 | 210.61 Million CNY | 22.3% |
| 2023 Q2 | 15.91 Million CNY | -92.44% |
| 2023 Q3 | 17.78 Million CNY | 11.79% |
| 2022 Q4 | 172.21 Million CNY | 784.81% |
| 2022 Q3 | 19.46 Million CNY | -12.39% |
| 2022 Q2 | 22.21 Million CNY | -84.58% |
| 2022 Q1 | 144.06 Million CNY | 202.3% |
| 2022 FY | - CNY | 23.18% |
| 2021 Q2 | 52.13 Million CNY | -55.64% |
| 2021 Q3 | 60.57 Million CNY | 16.19% |
| 2021 Q1 | 117.53 Million CNY | -23.48% |
| 2021 FY | - CNY | -25.3% |
| 2021 Q4 | 47.65 Million CNY | -21.33% |
| 2020 Q3 | 69.78 Million CNY | 3.54% |
| 2020 FY | - CNY | -11.44% |
| 2020 Q1 | 164.61 Million CNY | 377.96% |
| 2020 Q2 | 67.4 Million CNY | -59.05% |
| 2020 Q4 | 153.58 Million CNY | 120.07% |
| 2019 Q2 | 115.79 Million CNY | -48.62% |
| 2019 FY | - CNY | -31.6% |
| 2019 Q3 | 147.81 Million CNY | 27.66% |
| 2019 Q1 | 225.37 Million CNY | -17.84% |
| 2019 Q4 | 34.44 Million CNY | -76.7% |
| 2018 Q2 | 146.73 Million CNY | -33.65% |
| 2018 Q4 | 274.32 Million CNY | 95.92% |
| 2018 Q1 | 221.14 Million CNY | 2.91% |
| 2018 FY | - CNY | 15.35% |
| 2018 Q3 | 140.01 Million CNY | -4.58% |
| 2017 Q4 | 214.89 Million CNY | 70.04% |
| 2017 FY | - CNY | 5.34% |
| 2017 Q1 | 189.3 Million CNY | -4.79% |
| 2017 Q2 | 143.85 Million CNY | -24.01% |
| 2017 Q3 | 126.38 Million CNY | -12.15% |
| 2016 Q1 | 163.51 Million CNY | -34.39% |
| 2016 Q3 | 133.24 Million CNY | 8.27% |
| 2016 FY | - CNY | 9.04% |
| 2016 Q2 | 123.06 Million CNY | -24.74% |
| 2016 Q4 | 198.83 Million CNY | 49.23% |
| 2015 Q4 | 249.22 Million CNY | 203.68% |
| 2015 FY | - CNY | 28.15% |
| 2015 Q3 | 82.06 Million CNY | -21.53% |
| 2015 Q2 | 104.58 Million CNY | -26.12% |
| 2015 Q1 | 141.56 Million CNY | -20.28% |
| 2014 Q4 | 177.58 Million CNY | 199.23% |
| 2014 Q2 | 83.38 Million CNY | -28.21% |
| 2014 Q3 | 59.34 Million CNY | -28.82% |
| 2014 FY | - CNY | 15.52% |
| 2014 Q1 | 116.13 Million CNY | -18.15% |
| 2013 Q4 | 141.89 Million CNY | 177.45% |
| 2013 FY | - CNY | 10.25% |
| 2013 Q3 | 51.14 Million CNY | -31.32% |
| 2013 Q1 | 118.24 Million CNY | 5.38% |
| 2013 Q2 | 74.45 Million CNY | -37.03% |
| 2012 Q2 | 59.71 Million CNY | -37.05% |
| 2012 FY | - CNY | 14.45% |
| 2012 Q1 | 94.86 Million CNY | -32.23% |
| 2012 Q3 | 81.77 Million CNY | 36.95% |
| 2012 Q4 | 112.2 Million CNY | 37.2% |
| 2011 FY | - CNY | 47.45% |
| 2011 Q4 | 139.98 Million CNY | 132.22% |
| 2011 Q1 | 76.04 Million CNY | -32.76% |
| 2011 Q2 | 56.4 Million CNY | -25.83% |
| 2011 Q3 | 60.28 Million CNY | 6.88% |
| 2010 Q4 | 113.09 Million CNY | 159.08% |
| 2010 Q2 | 38.79 Million CNY | 45.15% |
| 2010 FY | - CNY | 46.56% |
| 2010 Q1 | 26.72 Million CNY | -66.13% |
| 2010 Q3 | 43.65 Million CNY | 12.51% |
| 2009 Q3 | 20.97 Million CNY | -22.11% |
| 2009 FY | - CNY | 25.63% |
| 2009 Q4 | 78.91 Million CNY | 276.27% |
| 2009 Q1 | 18.73 Million CNY | 0.0% |
| 2009 Q2 | 26.92 Million CNY | 43.73% |
| 2008 FY | - CNY | 15.22% |
| 2007 FY | - CNY | 0.0% |